

## **Gene Section**

Mini Review

# AIFM2 (apoptosis-inducing factor, mitochondrion-associated, 2)

#### Miroslav Varecha

Centre for Biomedical Image Analysis, Faculty of Informatics, Masaryk University, Botanicka 68a, Brno 60200, Czech Republic (MV)

Published in Atlas Database: June 2009

Online updated version: http://AtlasGeneticsOncology.org/Genes/AIFM2ID41842ch10q22.html

DOI: 10.4267/2042/44747

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. © 2010 Atlas of Genetics and Cytogenetics in Oncology and Haematology

## **Identity**

Other names: AMID; PRG3; RP11-367H5.2

**HGNC (Hugo):** AIFM2 **Location:** 10q22.1

## **DNA/RNA**


#### Description

The gene spans approximately 20.66 kb. Number of exons: 14, minus strand.

#### **Transcription**

The length of AIFM2 transcript is 3240 bp.

### **Protein**



Stably transfected (by lipofection) living cells U-2 OS (human osteosarcoma) cell line with plasmid producing red fluorescent fusion protein AIFM2-tHcRed.

#### Description

AIFM2 is oxidoreductase of 373 AA lenght. It is predicted to take part in caspase-independent apoptosis similarly to homologous AIFM1 (AIF, PDCD8). AIFM2 is p53-responsive gene and production of AIFM2 was found to be suppressed in many human cancers.

#### Expression

AIFM2 was detected in most healthy tissues in form of two transcripts (1.8 and 4.0 kb). It is highly expressed in heart, moderately in liver and skeletal muscles, and expressed at low levels in placenta, lung, kidney, and pancreas.

#### Localisation

Cytoplasmic side of cellular membranes.

#### **Function**

Oxidoreductase, that may be important in mediating a TP53/p53-dependent apoptotic response. Predicted to be caspase-independent effector of apoptotic cell death, but not shown by other authors. Function of this protein is thus unknown.

#### Homology

Homologous to AIFM1 (AIF, PDCD8). They share 22% aminoacid identity. It belongs to the FAD-dependent oxidoreductase family.

## Implicated in

#### Apoptosis and Cancer

#### Note

AIFM2 expression was found to be activated by overexpression of p53, which leads to cell cycle arrest

or apoptosis. Inactivation of p53 was observed in many human cancers.

#### References

Ohiro Y, Garkavtsev I, Kobayashi S, Sreekumar KR, Nantz R, Higashikubo BT, Duffy SL, Higashikubo R, Usheva A, Gius D, Kley N, Horikoshi N. A novel p53-inducible apoptogenic gene, PRG3, encodes a homologue of the apoptosis-inducing factor (AIF). FEBS Lett. 2002 Jul 31;524(1-3):163-71

Wu M, Xu LG, Li X, Zhai Z, Shu HB. AMID, an apoptosis-inducing factor-homologous mitochondrion-associated protein, induces caspase-independent apoptosis. J Biol Chem. 2002 Jul 12;277(28):25617-23

Wu M, Xu LG, Su T, Tian Y, Zhai Z, Shu HB. AMID is a p53-inducible gene downregulated in tumors. Oncogene. 2004 Sep 2:23(40):6815-9

Marshall KR, Gong M, Wodke L, Lamb JH, Jones DJ, Farmer PB, Scrutton NS, Munro AW. The human apoptosis-inducing protein AMID is an oxidoreductase with a modified flavin cofactor and DNA binding activity. J Biol Chem. 2005 Sep 2;280(35):30735-40

Mei J, Webb S, Zhang B, Shu HB. The p53-inducible apoptotic protein AMID is not required for normal development and tumor suppression. Oncogene. 2006 Feb 9;25(6):849-56

Gong M, Hay S, Marshall KR, Munro AW, Scrutton NS. DNA binding suppresses human AIF-M2 activity and provides a connection between redox chemistry, reactive oxygen species, and apoptosis. J Biol Chem. 2007 Oct 12;282(41):30331-40

Varecha M, Amrichová J, Zimmermann M, Ulman V, Lukásová E, Kozubek M. Bioinformatic and image analyses of the cellular localization of the apoptotic proteins endonuclease G, AIF, and AMID during apoptosis in human cells. Apoptosis. 2007 Jul;12(7):1155-71

Bilyy R, Kit Y, Hellman U, Stoika R. AMID: new insights on its intracellular localization and expression at apoptosis. Apoptosis. 2008 May;13(5):729-32

This article should be referenced as such:

Varecha M. AIFM2 (apoptosis-inducing factor, mitochondrion-associated, 2). Atlas Genet Cytogenet Oncol Haematol. 2010; 14(5):435-436.